Abstract
The short-term beat-to-beat variability of cardiac action potential duration (SBVR) occurs as a random alteration of the ventricular repolarization duration. SBVR has been suggested to be more predictive of the development of lethal arrhythmias than the action potential prolongation or QT prolongation of ECG alone. The mechanism underlying SBVR is not completely understood but it is known that SBVR depends on stochastic ion channel gating, intracellular calcium handling and intercellular coupling.
Coupling of single cardiomyocytes significantly decreases the beat-to-beat changes in action potential duration (APD) due to the electrotonic current flow between neighboring cells. The magnitude of this electrotonic current depends on the intercellular gap junction resistance. Reduced gap junction resistance causes greater electrotonic current flow between cells, and reduces SBVR.
Myocardial ischaemia (MI) is known to affect gap junction channel protein expression and function. MI increases gap junction resistance that leads to slow conduction, APD and refractory period dispersion, and an increase in SBVR. Ultimately, development of reentry arrhythmias and fibrillation are associated post-MI. Antiarrhythmic drugs have proarrhythmic side effects requiring alternative approaches. A novel idea is to target gap junction channels. Specifically, the use of gap junction channel enhancers and inhibitors may help to reveal the precise role of gap junctions in the development of arrhythmias. Since cell-to-cell coupling is represented in SBVR, this parameter can be used to monitor the degree of coupling of myocardium.
Keywords: Heart, gap junction, beat-to-beat variability, arrhythmia.
Current Pharmaceutical Design
Title:Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias
Volume: 21 Issue: 8
Author(s): Janos Magyar, Tamas Banyasz, Norbert Szentandrassy, Kornel Kistamas, Peter P. Nanasi and Jonathan Satin
Affiliation:
Keywords: Heart, gap junction, beat-to-beat variability, arrhythmia.
Abstract: The short-term beat-to-beat variability of cardiac action potential duration (SBVR) occurs as a random alteration of the ventricular repolarization duration. SBVR has been suggested to be more predictive of the development of lethal arrhythmias than the action potential prolongation or QT prolongation of ECG alone. The mechanism underlying SBVR is not completely understood but it is known that SBVR depends on stochastic ion channel gating, intracellular calcium handling and intercellular coupling.
Coupling of single cardiomyocytes significantly decreases the beat-to-beat changes in action potential duration (APD) due to the electrotonic current flow between neighboring cells. The magnitude of this electrotonic current depends on the intercellular gap junction resistance. Reduced gap junction resistance causes greater electrotonic current flow between cells, and reduces SBVR.
Myocardial ischaemia (MI) is known to affect gap junction channel protein expression and function. MI increases gap junction resistance that leads to slow conduction, APD and refractory period dispersion, and an increase in SBVR. Ultimately, development of reentry arrhythmias and fibrillation are associated post-MI. Antiarrhythmic drugs have proarrhythmic side effects requiring alternative approaches. A novel idea is to target gap junction channels. Specifically, the use of gap junction channel enhancers and inhibitors may help to reveal the precise role of gap junctions in the development of arrhythmias. Since cell-to-cell coupling is represented in SBVR, this parameter can be used to monitor the degree of coupling of myocardium.
Export Options
About this article
Cite this article as:
Magyar Janos, Banyasz Tamas, Szentandrassy Norbert, Kistamas Kornel, Nanasi Peter P. and Satin Jonathan, Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias, Current Pharmaceutical Design 2015; 21 (8) . https://dx.doi.org/10.2174/1381612820666141029102443
DOI https://dx.doi.org/10.2174/1381612820666141029102443 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry Inhibitory Effect of PD-1/PD-L1 and Blockade Immunotherapy in Leukemia
Combinatorial Chemistry & High Throughput Screening Role of Coronary Microvascular Endothelial Dysfunction in the Development of Heart Failure
Current Cardiology Reviews Role of Pancreatic β-Cell Death and Cell Death-Associated Inflammation in Diabetes
Current Molecular Medicine Reactive Oxygen Species in Vascular Wall
Cardiovascular & Hematological Disorders-Drug Targets Cannabinoids (CBD, CBDHQ and THC): Metabolism, Physiological Effects, Electron Transfer, Reactive Oxygen Species and Medical Use
The Natural Products Journal Outcome of Heart Failure with Preserved Ejection Fraction: A Multicentre Spanish Registry
Current Cardiology Reviews The Golden Spice for Life: Turmeric with the Pharmacological Benefits of Curcuminoids Components, Including Curcumin, Bisdemethoxycurcumin, and Demethoxycurcumins
Current Organic Synthesis Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews Ivabradine for Uncontrolled Sinus Tachycardia in Thyrotoxic Cardiomyopathy - Case Report
Endocrine, Metabolic & Immune Disorders - Drug Targets Oxidative Stress and Lipid Peroxidation in Prolonged Users of Methamphetamine
Drug Metabolism Letters Antipsychotic-Induced Electrocardiographic Changes: A Comparative Study Between Olanzapine and Risperidone
Current Psychopharmacology Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design Bcl-2 Family Proteins Regulate Apoptosis and Epithelial to Mesenchymal Transition by Calcium Signals
Current Pharmaceutical Design Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Diabetes
Current Pharmaceutical Design Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology